- Over one-third of hospitalized individuals are in danger of suffering neurological issues
- Traditional EEGs present various challenges, including cross-contamination
- NeuroCap(TM) makes EEGs more accessible, sanitary
Brain Scientific (OTCQB: BRSF), a commercial-stage healthcare company with two FDA-cleared products, provides next-gen solutions to the neurology market. Neurological care that reduces the opportunity of cross-contamination is critically needed in the effort to combat COVID-19.
According to the CDC’s national forecast data, the United States is predicted to report a new record of COVID-19 cases, anticipated to number between 1 million and 2.3 million new cases the week ending Jan. 2, 2021 (https://ibn.fm/NveF2). A recent Chinese study documented the neurological impacts of COVID-19 on 214 patients under treatment across three hospitals, noting that 36.4% of those patients presented neurological manifestations (https://ibn.fm/OOcAx), which often calls for electroencephalogram (“EEG”) testing. That number amounts to over one-third of hospitalized individuals. The need for EEG-trained technicians to administer the anticipated tests is quickly accelerating.
Every day scientists are learning more about COVID-19. More data is needed as the world works to flatten the curve and discover long-term effects and treatments. To better understand its impact on the brain, EEGs must become more accessible.
Traditional EEGs present various challenges. A trained technician is needed to fit, monitor and record the process. The test can take between 30 to 45 minutes to administer patient and requires close proximity, within eight inches, to the infected patient. The EEG, sensors and wires, if not fully sterilized, can also be a source of contamination.
The solution is a disposable EEG headset, Brain Scientific’s NeuroCap(TM). FDA cleared, this disposable pre-gelled EEG headset has 22 electrodes and 19 active EEG channels and is fully compatible with existing amplifiers. Because it is designed for a single use, it minimizes cross-contamination. The NeuroCap takes only five minutes to apply and can be administered by any clinical staff member; trained technicians are not required.
Knowledge-based decision making during this worldwide health pandemic is vital. Acquiring that knowledge in cost-effective ways that reduce the chance of cross-contamination is possible with BRSF’s innovative NeuroCap.
For more information, visit the company’s website at www.BrainScientific.com.
NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
San Francisco, California
BioMedWire is part of the InvestorBrandNetwork.